A preclinical study showed that in vitro application of ceritinib combined with a PD-L1 inhibitor in the treatment of ALK-rearranged NSCLC promotes lymphocyte proliferation and activation, inhibits PD-L1 expression, and enhances lymphocyte cytotoxicity and cell death. The gene discussed is CD274; the disease is non-small cell lung carcinoma.